Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Schedule of Bio-Reference Purchase Price Allocation (Details)

v3.3.1.900
Acquisitions, Investments, and Licenses - Schedule of Bio-Reference Purchase Price Allocation (Details) - USD ($)
$ in Thousands
 1 Months Ended
Aug. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
 [1]
Dec. 31, 2013
Business Acquisition [Line Items]        
Goodwill   $ 743,348 [1] $ 224,292 $ 226,373
Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Value of OPKO Common Stock issued to Bio-Reference shareholders $ 947,889      
Value of equity interest issued or issuable 2,259      
Total purchase price 950,148      
Cash and cash equivalents 15,800      
Accounts receivable 168,164      
Inventory 19,674      
Other current assets, principally deferred tax assets 61,135      
Current assets 264,773      
Property, plant and equipment 112,457      
Intangible assets 542,900      
Goodwill 441,158 $ 441,158    
Investments 5,326      
Other assets 13,265      
Total assets 1,379,879      
Accounts payable (77,908)      
Accrued expenses (30,848)      
Income taxes payable (437)      
Lines of credit and notes payable (65,701)      
Capital lease obligations (18,293)      
Deferred tax liability (non-current) (236,544)      
Total purchase price 950,148      
Trade names | Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Intangible assets 47,100      
Customer relationships | Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Intangible assets 395,200      
Technology | Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Intangible assets $ 100,600      
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.